Overview

Study to Evaluate the Relative Bioavailability of a New Formulation of NPT 2042 Soft-Gelatin Capsules Compared to the Original Formulation of NPT 2042

Status:
RECRUITING
Trial end date:
2025-11-15
Target enrollment:
Participant gender:
Summary
A Single-center, Open-label, Single-dose, Three-period, Fixed Sequence Study to Evaluate the Relative Bioavailability of a New Formulation of NPT 2042 Soft-Gelatin Capsules
Phase:
PHASE1
Details
Lead Sponsor:
NeuroPro Therapeutics, Inc.